Among the most closely followed pharmaceutical launches of 2026 is Novo Nordisk's CagriSema, a combination of semaglutide (2.4 mg) and cagrilintide designed to treat obesity and type 2 diabetes.
Eli Lilly, meanwhile, continues developing orforglipron, an oral GLP-1 receptor agonist. Unlike already-known injectable treatments, its pill form could make this kind of therapy more accessible to many patients.
Lilly has said it expects a decision from US regulators on this drug during 2026, which has generated significant anticipation in the medical community and among patient associations.